Copied
 
 
Formål
Formål
Selskabets formål er at drive virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi, og hermed forbundet virksomhed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 03.12.2012 (4164 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 03.12.2012 (4164 dage).
Ingen historik.
Branche
Branche
Forskning og eksperimentel udvikling indenfor bioteknologi (721100).
Sidst opdateret den 02.01.2013 og angivet som gældende fra 03.12.2012 (4164 dage).
Ingen historik.
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 03.12.2012 (4164 dage).
Ingen historik.
Revisor
Revisor
EY Godkendt Revisionspartnerselskab
Sidst opdateret den 16.05.2019 og angivet som gældende fra 15.05.2019 (1810 dage).
Form
Virksomhedsform
80.
Sidst opdateret den 05.12.2012 og angivet som gældende fra 03.12.2012 (4164 dage).
Ingen historik.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af et bestyrelsesmedlem og en direktør i forening eller af den samlede bestyrelse.
Sidst opdateret den 26.10.2020 og angivet som gældende fra 26.10.2020 (1280 dage).
Fortolkning (3 tegningsmuligheder)
2 bestyrelsesmedlemmer +
1 bestyrelsesmedlem + 1 direktør
bestyrelsen
HistorikStartStop
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af et bestyrelsesmedlem og en direktør i forening eller af den samlede bestyrelse26.10.2020
Selskabet tegnes af en direktør03.12.201225.10.2020
Ansatte
28.04.2024
Kapital
28.04.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:statsautoriseret revisor
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):We have audited the financial statements of Galecto Biotech ApS for the financial year 1 January – 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January – 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management's review Management is responsible for management's review. Our opinion on the financial statements døs not cover management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
28.04.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
28.04.2024
Ingen nuværende registrering.
Ingen historik.